Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Halozyme Therapeutics (HALO) PT Lowered to $19 at BMO Capital
November 7, 2018 9:00 AM ESTBMO Capital analyst Do Kim lowered the price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $21.00) while maintaining a Market Perform rating.
The analyst commented, "We expect HALO shares to remain range bound until PEGPH20 Phase 3 PFS data in 1H19, unless a... More
